|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2005-5-30
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) inhibitors are in clinical development in cancer treatment. Preclinical studies have shown potential antitumor efficacy of these agents in combination with chemotherapy or with radiotherapy. However, controversial results have been obtained in different clinical trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/N-(4-bromo-2-fluorophenyl)-6-methoxy...,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16 Suppl 4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
iv61-68
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15923432-Antibodies, Monoclonal,
pubmed-meshheading:15923432-Antineoplastic Agents,
pubmed-meshheading:15923432-Carboplatin,
pubmed-meshheading:15923432-Carcinoma, Squamous Cell,
pubmed-meshheading:15923432-Cell Cycle,
pubmed-meshheading:15923432-Cell Line, Tumor,
pubmed-meshheading:15923432-Cisplatin,
pubmed-meshheading:15923432-Dose-Response Relationship, Drug,
pubmed-meshheading:15923432-Esophageal Neoplasms,
pubmed-meshheading:15923432-Humans,
pubmed-meshheading:15923432-Organoplatinum Compounds,
pubmed-meshheading:15923432-Paclitaxel,
pubmed-meshheading:15923432-Piperidines,
pubmed-meshheading:15923432-Quinazolines,
pubmed-meshheading:15923432-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15923432-Taxoids
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
|
|
pubmed:affiliation |
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Napoli, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
